Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110360 | 1.00 | UGT2B7 (1.00) | UGT2B7MEN1KMT2AATMCYP2D6 | |
| SCHEMBL445001 | 1.00 | UGT2B7 (1.00) | UGT2B7MEN1KMT2AATMCYP2D6 | |
| SCHEMBL29609979 | 1.00 | UGT2B7 (1.00) | UGT2B7MEN1KMT2AATMCYP2D6 | |
| SCHEMBL30552890 | 1.00 | UGT2B7 (1.00) | UGT2B7MEN1KMT2AATMCYP2D6 | |
| SCHEMBL29397925 | 1.00 | UGT2B7 (1.00) | UGT2B7MEN1KMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL27389834 | 0.98 | UGT2B7 (0.96) | UGT2B7MEN1KMT2AATMCYP2D6 | |
| SCHEMBL10785006 | 0.93 | UGT2B7 (0.88) | UGT2B7MEN1KMT2AATMCYP2D6 | |
| SCHEMBL5610446 | 0.91 | UGT2B7 (0.82) | UGT2B7MEN1KMT2AATMCYP2D6 | |
| Acetic Acid SCHEMBL7514323 | 0.90 | UGT2B7 (0.81) | UGT2B7MEN1KMT2AATMCYP2D6 | |
| SCHEMBL3151796 | 0.84 | UGT2B7 (0.73) | UGT2B7MEN1KMT2AATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110002961-B | Method for racemization-free synthesis of chiral alcohol | 三峡大学 | 2022-05-03 | — | — | CN | claimed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| CN-110002961-B | Method for racemization-free synthesis of chiral alcohol | 三峡大学 | 2022-05-03 | — | — | CN | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| EP-2838643-B1 | IMPROVED DILUTE CHEMICAL REACTION PROCESS WITH MEMBRANE SEPARATION STEP | VLAAMSE INSTELLING VOOR TECH ONDERZOEK VITO (BE) | 2021-06-16 | — | — | EP | disclosed |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ROIVANT SCIENCES GMBH (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES, GmbH (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
| WO-2002064130-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
| US-6218581-B1 | SOLVENT EXTRACTION OF WATER SOLUBLE PROTEIN FROM BEAN OR GRAIN; ISOLATION, PURIFICATION OF ACYLATED FORM; HYDROLYSIS | SANYO SHOKUHIN CO., LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0978567-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOLS | SANYO SHOKUHIN CO., LTD. (JP) | 2000-02-09 | — | — | EP | disclosed |
| US-5883132-A | MULTISTAGE REACTION OF AMIDATION, ACTIVATION, COUPLING AND HYDROLYSIS | FOURNIER INDUSTRIE ET SANTE (FR) | 1999-03-16 | — | — | US | disclosed |
| EP-0755380-B1 | 15-DEOXYSPERGUALIN ANALOGS, THERAPEUTICAL USE THEREOF, AND METHOD FOR PREPARING SAME | FOURNIER IND & SANTE (FR) | 1998-10-14 | — | — | EP | disclosed |
| EP-0755380-A1 | 15-DEOXYSPERGUALIN ANALOGS, THERAPEUTICAL USE THEREOF, AND METHOD FOR PREPARING SAME | FOURNIER INDUSTRIE ET SANTE (FR) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996024579-A1 | 15-DEOXYSPERGUALIN ANALOGS, THERAPEUTICAL USE THEREOF, AND METHOD FOR PREPARING SAME | FOURNIER INDUSTRIE ET SANTE (FR) | 1996-08-15 | — | — | WO | disclosed |
| WO-1995013284-A1 | ASYMMETRIC HYDROBORATION | ISIS INNOVATION LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | UGT2B7 1593/4885MEN1 629/4885KMT2A 1610/4885 |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | UGT2B7 1593/4885MEN1 629/4885KMT2A 1610/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | UGT2B7 1593/4885MEN1 629/4885KMT2A 1610/4885 |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | UGT2B7 1775/4885MEN1 4860/4885KMT2A 2463/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | UGT2B7 1593/4885MEN1 629/4885KMT2A 1610/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | UGT2B7 1593/4885MEN1 629/4885KMT2A 1610/4885 |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | UGT2B7 1593/4885MEN1 629/4885KMT2A 1610/4885 |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | UGT2B7 1593/4885MEN1 629/4885KMT2A 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.